Biomarkers derived from functional MRI have potential to monitor response to therapy and stratify patient care. In this study of 22 patients with rectal cancer we evaluated the relative merits of using OE-MRI, DCE-MRI and DWI biomarkers to assess response to chemoradiotherapy. We show that OE-MRI is feasible in rectal cancer tumours and provides complementary information to that measured by DWI and DCE-MRI. Data suggests that OE-MRI may be useful as a pharmacodynamic tool to identify hypoxia modification as this was present by day 14, but not at day 7 into therapy.
This abstract and the presentation materials are available to members only; a login is required.